|Targets||Akt | Ser/Thr Protease|
|Description||ARQ-092, also called as Miransertib, is an oral activie, potent and selective AKT inhibitor with IC50= 5.0 nM against AKT1, 4.5 nM against AKT2 and 16 nM against AKT3. ARQ-092 inhibits the PI3K/AKT signaling pathway due to inhibition of the activity of AKT in a non-ATP competitive manner. This may lead to the reduction in tumor cell proliferation and the induction of tumor cell apoptosis.|
|Related CAS||1313881-70-7 (free); 1313883-00-9 (HCl); 1817727-87-9 (3HCl)|
|Synonyms||3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine; ARQ092; ARQ-092; ARQ 092; Miransertib|
PHT-427 is an AKT inhibitor that inhibits AKT and PDPK1 at low micromolar concentrations in numerous cancer cell lines and exhibits good oral anti-tumor activit...
Crosstide, a peptide analog of glycogen synthase kinase α/β fusion protein sequence, acts as a substrate for Akt (PKB) (Km=4µM) and is useful in phosphocellulos...
Aprotinin is the small protein bovine pancreatic trypsin inhibitor (BPTI). It is an antifibrinolytic molecule that inhibits trypsin and related proteolytic enzy...
Ono 3403, a derivative of camostat mesilate and has a higher protease-inhibitory activity, is a synthetic serine protease inhibitor that inhibits lipopolysaccha...
XL-418 is a 70 kDa ribosomal protein S6 kinase and Proto oncogene protein c-akt inhibitor. It can inhibit the activities of PKB and p70S6K, both acting downstre...
AT7867 also inhibits structurally related AGC kinases p70S6K and PKA with IC50 of 20 nM and 85 nM, respectively. AT7867 shows ATP-competitive activity to Akt2 w...
CFI-400945 is a PLK4 (polo-like kinase 4) inhibitor with potential antineoplastic activity originated by University Health Network. It can selectively inhibit P...
BAY-1217389, an imidazopyridazin derivative, has been found to be a TTK protein inhibitor that could probably be effective as an antineoplastic agent and also b...
Gabexate is a serine protease inhibitor that inhibits trypsin (IC50= 9.4μM), plasmin (IC50= 30μM), plasma kallikrein (IC50= 41μM) and thrombin (IC50= 110μM). It...
A-674563 is an Akt1 inhibitor with Ki of 11 nM, modest potent to PKA and >30-fold selective for Akt1 over PKC.
PLS-123 is a novel covalent irreversible Bruton's Tyrosine Kinase inhibitor. PLS-123 shows potent anti-proliferative effects in multiple cellular and in vivo pr...
Leupeptin reversibly inhibits serine proteinases (trypsin (Ki=3.5 nM), plasmin (Ki= 3.4 nM), porcine kallikrein), and cysteine proteinases (papain, cathepsin B ...
Akt1 and Akt2-IN-1
Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 and Akt2 with the IC50 of 3.5 nM and 42 nM respectively. It has potent and balanced activity. It is depend...
CFI-401870 is a TTK (tyrosine threonine kinase) Inhibitor with IC50 value < 10 nM. CFI-401870 showed low off-target activity (>500×) and microsomal stability (T...
AZD5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD5363 binds to ...
SC66 is a novel and potent AKT inhibitor, which reduced cell viability in a dose- and time-dependent manner, inhibited colony formation and induced apoptosis in...
SC79 is a brain-penetrable Akt phosphorylation activator and an inhibitor of Akt-PH domain translocation.
Ipatasertib, also known as GDC-0068, is a highly selective pan-Akt inhibitor targeting Akt1/2/3 (IC50= 5 nM/18 nM/8 nM in cell-free assays) with 620-fold select...
RO9021 is ATP-competative and selective inhibitor of spleen tyrosine kinase (SYK) with IC50 value of 5.6 nM. RO-9021 is a highly selective SYK inhibitor with lo...
3CAI is an orally active, potent and specific allosteric inhibitor of Akt1 and Akt2 that directly binds to Ak1 and Akt2 in an ATP noncompetitive manner.